Literature DB >> 21461580

Functional significance of B7-H1 expressed by human uveal melanoma cells.

Renbing Jia1, Zhijun Jiao, Xiaofang Xu, Jing Wang, Yixiong Zhou, Xin Song, Shengfang Ge, Xianqun Fan.   

Abstract

B7-H1, a recently described B7 family member, has been reported to negatively regulate T-cell function in most cancer cells. In this study, we sought to investigate B7-H1 expression in four uveal melanoma (UM) cells (OCM1, SP6.5, OM431 and VUP) to determine the functional significance of B7-H1 expression in T-cell immune response. Using flow cytometry (FCM), we demonstrated that SP6.5 cells had high B7-H1 protein expression, while the other three UM cell lines had none. However, all four UM cell lines expressed B7-H1 mRNA, as confirmed by reverse transcription-polymerase chain reaction. In co-culture experiments using B7-H1-expressing UM cells with T-cells, FCM to determine CD69 expression in T-cells revealed that SP6.5 cell-related B7-H1 inhibited T-cell activation. This effect was eliminated by B7-H1-targeted RNA interference. An Annexin V/PI double staining assay further showed that B7-H1 expressed by SP6.5 cells did not increase the apoptosis of T-cells, though it was found in a variety of other solid tumors. In conclusion, all the UM cell lines constitutively expressed B7-H1 mRNA, while B7-H1 protein was expressed at different levels. UM-related B7-H1 expression negatively regulated T-cell immune response through the inhibition of T-cell activation, and not through the promotion of T-cell apoptosis. This provides new insight into anti-tumor immunity against B7-H1-expressing UM cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21461580     DOI: 10.3892/mmr.2010.397

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

Review 1.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

2.  Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors.

Authors:  Xiaolin Huang; Li Wang; He Zhang; Haibo Wang; Xiaoping Zhao; Guanxiang Qian; Jifan Hu; Shengfang Ge; Xianqun Fan
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

Review 3.  The biology of uveal melanoma.

Authors:  Adriana Amaro; Rosaria Gangemi; Francesca Piaggio; Giovanna Angelini; Gaia Barisione; Silvano Ferrini; Ulrich Pfeffer
Journal:  Cancer Metastasis Rev       Date:  2017-03       Impact factor: 9.264

4.  Study of Cinobufagin as a Promising Anticancer Agent in Uveal Melanoma Through Intrinsic Apoptosis Pathway.

Authors:  Leilei Zhang; Xiaolin Huang; Tao Guo; Huixue Wang; Haiyan Fan; Li Fang
Journal:  Front Oncol       Date:  2020-04-02       Impact factor: 6.244

5.  A novel anticancer therapy that simultaneously targets aberrant p53 and Notch activities in tumors.

Authors:  Yuting Yao; Li Wang; He Zhang; Haibo Wang; Xiaoping Zhao; Yidan Zhang; Leilei Zhang; Xianqun Fan; Guanxiang Qian; Ji-Fan Hu; Shengfang Ge
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

6.  Targeted silencing of MART-1 gene expression by RNA interference enhances the migration ability of uveal melanoma cells.

Authors:  Yidan Zhang; Renbing Jia; Jing Wang; Xiaofang Xu; Yuting Yao; Shengfan Ge; Xianqun Fan
Journal:  Int J Mol Sci       Date:  2013-07-19       Impact factor: 5.923

7.  Differential expression of TYRP1 in adult human retinal pigment epithelium and uveal melanoma cells.

Authors:  Chun Qiu; Peng Li; Jianjun Bi; Qing Wu; Linna Lu; Guanxiang Qian; Renbing Jia; Rong Jia
Journal:  Oncol Lett       Date:  2016-02-25       Impact factor: 2.967

8.  Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.

Authors:  Yong Qin; Kathryn Bollin; Mariana Petaccia de Macedo; Fernando Carapeto; Kevin B Kim; Jason Roszik; Khalida M Wani; Alexandre Reuben; Sujan T Reddy; Michelle D Williams; Michael T Tetzlaff; Wei-Lien Wang; Dan S Gombos; Bita Esmaeli; Alexander J Lazar; Patrick Hwu; Sapna P Patel
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 12.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.